2019
DOI: 10.1002/acm2.12777
|View full text |Cite
|
Sign up to set email alerts
|

Validation of the RayStation Monte Carlo dose calculation algorithm using a realistic lung phantom

Abstract: PurposeOur purposes are to compare the accuracy of RaySearch's analytical pencil beam (APB) and Monte Carlo (MC) algorithms for clinical proton therapy and to present clinical validation data using a novel animal tissue lung phantom.MethodsWe constructed a realistic lung phantom composed of a rack of lamb resting on a stack of rectangular natural cork slabs simulating lung tissue. The tumor was simulated using 70% lean ground lamb meat inserted in a spherical hole with diameter 40 ± 5 mm carved into the cork s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
14
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 14 publications
(17 citation statements)
references
References 42 publications
1
14
0
Order By: Relevance
“…The Monte Carlo calculation algorithm is considered to be more accurate in heterogeneous environments, like the lung cohort [ 72 ]. As expected, Monte Carlo calculations had little effect on the OARs, but showed an approximate 5% reduction in mean CTV D95 compared with the clinical algorithm utilised, which is in agreement with other reports [ 73 , 74 ]. Unfortunately, Monte Carlo-based optimisation is not currently available within the Eclipse treatment planning system but follow-up studies utilising this are warranted.…”
Section: Discussionsupporting
confidence: 92%
“…The Monte Carlo calculation algorithm is considered to be more accurate in heterogeneous environments, like the lung cohort [ 72 ]. As expected, Monte Carlo calculations had little effect on the OARs, but showed an approximate 5% reduction in mean CTV D95 compared with the clinical algorithm utilised, which is in agreement with other reports [ 73 , 74 ]. Unfortunately, Monte Carlo-based optimisation is not currently available within the Eclipse treatment planning system but follow-up studies utilising this are warranted.…”
Section: Discussionsupporting
confidence: 92%
“…The results reported in the current study complement previous findings 1,5,7,8 by adding the impact of variations in spot sizes and positions in robustly optimized PBS lung plans. Due to the availability of the Monte Carlo algorithm in commercially available TPS, researchers are recommending the Monte Carlo algorithm for the optimization and dose calculations in the proton lung plans 14–17 . The current study provides additional information regarding the impact of spot size and position errors on the dose distributions of the lung plans, which were robustly optimized (SFO technique) and calculated using the Monte Carlo algorithm.…”
Section: Discussionmentioning
confidence: 99%
“…In commercial proton treatment planning systems (TPS), Monte Carlo algorithms have been shown to be more accurate in estimating spot sizes than analytical pencil beam algorithms. 12,13 A growing number of publications [14][15][16][17] have now recommended using the Monte Carlo algorithm for the dose calculations in PBS lung cancer. Recently, robust optimization 14,18 feature has been made available in the clinical environment, whereas previous studies 1,[5][6][7][8] did not address the impact of variation in spot size on robustly optimized clinical plans.…”
Section: Introductionmentioning
confidence: 99%
“…Despite being subject to scrutiny, the pencil beam algorithm (PBA) in PT provides fast speeds at the potential sacrifice of accuracy in complex tissue inhomogeneities. The gold standard for accuracy is the MC simulation and related codes are only recently introduced to the clinics, fostered by past and on-going efforts to develop clinical dose engines [11,12].…”
Section: Introductionmentioning
confidence: 99%
“…Most notably, investigations with anthropomorphic lung phantoms suggest that application of commercial TPSs using analytical algorithms for the treatment of lung tumors should be deemed unfit for clinical use or used with extreme caution [15]. The lateral dose distribution computed by PBA in the lung and in bone interfaces may reach a level of inaccuracy around 30% [16,17], while commercial MC-based TPSs can improve the accuracy of dose calculation in the lung/bone interfaces or through inhomogeneities within ~5% [12,17]. Despite being considered clinically tolerable, another source of uncertainty in proton therapy of lung originates from the heterogeneous structure of the lung itself, which leads to a degradation of the Bragg peak and a wider distal fall-off [18].…”
Section: Introductionmentioning
confidence: 99%